Lipoprotein (a) (Labkit)

Lipoprotein (a) (Labkit)

Product Description

Immunoturbidimetric method

Available Options:

REF Volume

Lipoprotein (a) is a low-density lipoprotein (LDL)–like molecule that has been linked to both coronary artery and cerebrovascular disease. Elevated levels of Lp (a) (>35–40 mg/dL) have been associated with premature CHD and evolve as an independent risk factor for ischemic stroke, even in normocholesterolemic and normolipidemic patients. This increased risk appears to result from two different mechanisms: cholesterol deposition in the arterial wall and inhibition of fibrinolysis.


The lipoprotein (a) molecule is composed of two components: apolipoprotein B (apo B) and apolipoprotein A (apo A). The apo A is different than apo A-1 found in HDL and responsible for reverse cholesterol transport, has a highly heterogeneous nature. The apo A portion shares significant structural homology with plasminogen, and it has been postulated that lipoprotein (a) may compete for plasminogen-binding sites on fibrin and endothelial cells, thereby inhibiting endogenous fibrinolysis.As a result, plasminogen activation, plasmin generation, and fibrinolysis are impaired in the presence of elevated Lp (a). Lp (a) can also bind to macrophages via a high-affinity receptor that promotes foam cell formation within atherosclerotic plaques. Because of its combined prothrombotic and proatherogenic properties, Lp (a) may influence CVD development, progression, and events through multiple mechanisms.A number of medical conditions have been associated with elevated lipoprotein (a) levels, particularly diabetes with poor glycemic control and renal impairment. 


National Lipid Association and the European Society of Cardiology / European Atherosclerosis Society do recommend Lp(a) measurement for patients with familial hypercholesterolemia, family history of premature CVD and / or elevated Lp(a) levels, personal history of premature CVD, recurrent CVD despite optimal statin treatment, inadequate percent LDL-C reduction response to statins, and ?10% 10-year risk of fatal or nonfatal CHD (per NLA) or ?3% 10-year risk of fatal CVD (per the European guidelines).

Product Features:


  • Immunoturbidimetric method.
  • Ready to use reagents.
  • No prozone effect up to 2250 mg/L.
  • Very good correlation with other commercially available reagents.
  • Calibrator is included in the pack.
  • AMR: between 5 and 800 mg/L.
  • For use on semiautomatic analyzers only
  • Can be programmed on fully automated instruments by making working reagents. (Please seek application specialist’s advice prior to procurement)
  • Controls-optional.



Additional documents

Request Quote *(NOTE : Before submiting this form. please check your provided information.)